神奈川県川崎市宮前区菅生2-16-1
聖マリアンナ医科大学病院 腫瘍内科

業績・書籍紹介

書籍

チャートでわかる! がん化学療法のリアル
1. チャートでわかる! がん化学療法のリアル
  • 聖マリアンナ医科大学病院腫瘍センター

ご購入はこちら

学会発表(国内学会)

2019年度
2019.05 第59回肝癌症例検討会
  • 直腸カルチノイド腫瘍術後3年9ヶ月で多発肝転移を発症した1症例
    土屋 淳一, 佐々木 大祐, 石井 将光, 四万村 司, 朝倉 武士, 津田 享志, 小池 淳樹, 大坪 毅人
2019.07 第17回日本臨床腫瘍学会学術集会
  • 私の腫瘍内科医としてのキャリア:大学病院の立場から
    中島貴子
  • <大腸がん診療における遺伝子関連検査等のガイダンス> 包括的ゲノムプロファイリング検査/リキッドバイオプシー
    砂川優
  • An observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
    Yu Sunakawa
  • Prospective study to investigate the clinical efficacy of G-CSF for Docetaxel + Cisplatin + 5-Fluorouracil (DCF) chemotherapy in patients with esophageal squamous cell carcinoma (ESCC).
    Mitsuhiro Sugawara, Chikatoshi Katada, Akinori Watanabe, Yasutoshi Sakamoto, Hiroki Hara, Hirofumi Fujii, Takako Nakajima, Takayuki Ando, Takashi Kojima, Hideki Ishijima, Ayumu Hosokawa, Yasuo Hamamoto, Manabu Muto, Makoto Tahara, Wasaburo Koizumi.
  • Update on phase II trial of cetuximab plus S–1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06.
    Yu Sunakawa, Wataru Ichikawa, Ken Hagiwara, Masahiro Tsuda, Akinori Takagane, Hisateru Yasui, Hironaga Satake, Tadamichi Denda, Yoshihiko Segawa, Hiroaki Tanioka, Masahito Kotaka, Mitsugu Kochi, Takanori Watanabe, Masato Nakamura, Akihito Tsuji, Satoshi Tani, Yuji Negoro, Kazutoshi Tobimatsu, Masahiro Takeuchi, Masashi Fujii
  • Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer.
    Masato Nakamura, Yu Sunakawa, Hiroyuki Okuyama, Masato Matsuura, Yuji Negoro, Taichi Yabuno, Takao Takahashi, Takao Tamura, Nobumichi Takeuchi, Hironaga Satake, Yuji Miyamoto, Masato Kataoka, Manabu Shiozawa, Akitaka Makiyama, Kazuma Kobayashi, Yutaro Kubota, Takashi Sekikawa, Masahiro Takeuchi, Wataru Ichikawa and Masashi Fujii
  • 2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC).
    薦田正人, 山本駿, 川上武志, 三谷誠一郎, 辻靖, 伊澤直樹, 川上賢太郎, 山本祥之, 津田孝志, 他
  • Association of gastric acid suppression with efficacy of immune checkpoint inhibitors.
    Naoki Izawa, Hisae Shiokawa, Risa Onuki, Koki Hamaji,Naoki Furuya,Hiroyuki Ohashi, Tomohiro Nishi, Shigeru Kasugai, Hiroyuki Takeda, Kumiko Umemoto, Hiroyuki Arai, Ayako Doi, Yoshiki Horie, Mami Hirakawa, Takuro Mizukami, Takashi Ogura, Takashi Tsuda, Yu Sunakawa, Takako Eguchi Nakajima
2019.09 第4回日本がんサポーティブケア学会
  • Call-to- Action for METAvivor 〜ABCC会議からの提案〜
    中島 貴子、大野真司、桜井なおみ、滝口裕一、森 雅人
  • in advanced solid cancer patients.
    水上 拓郎, 宮路 天平, 川口 崇, 原 浩樹, 津田 享志, 山口 拓洋, 室 圭, 中島 貴子
2019.09 第78回日本癌学会学術総会
  • Has vcure become a realistic goal for metastatic cancer?
    Takako Nakajima
2019.10 第57回日本癌治療学会学術集会
  • Identification of Site-specific Genome Alterations in Metastatic Colorectal Cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.
    Takuro Mizukami, Masaki Takahashi, Yu Sunakawa, Satoshi Yuki, Yoshinori Kagawa, Atsuo Takashima, Kyoko Kato, Hiroki Hara, Tadamichi Denda, Toshikazu Moriwaki, Manabu Shiozawa, Eiji Oki, Wataru Okamoto, Takayuki Yoshino, Takako Eguchi Nakajima.
  • International clinical practivce guideline for metastatic liver tumor: Chmotherapy.
    Takako Eguchi Nakajima, Takuro Mizukami, Hiroyuki Takeda, Hisato Kawakami, Naohiro Okano, Makoto Ueno, Susumu Hijioka, Masato Ozaka, Takayuki Ueno, Yoichi Naito, Junji Furuse.
  • がん腫別に考える体重減少とその要因:胃癌
    中島貴子
  • Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients.
    Naoki Izawa, Hisae Shiokawa, Risa Onuki, Koki Hamaji, Naoki Furuya, Hiroyuki Ohashi, Tomohiro Nishi, Shigeru Kasugai, Hiroyuki Arai, Ayako Doi,Yoshiki Horie, Mami Hirakawa, Takuro Mizukami, Takashi Ogura, Takashi Tsuda, Yu Sunakawa, Takako Nakajima.
  • 進行大腸がんにおけるctDNA中のRAS変異と抗EGFR抗体薬リチャレンジ治療の効果
    辻晃仁,砂川優,中村将人,石崎雅浩,片岡政人,佐竹悠良,北薗正樹,柳澤秀之,川本泰之,倉持英和,大堀久詔,中村路夫,竹内正弘,藤井雅志, 市川度
2018年度
2018.08 第3回日本がんサポーティブケア学会学術集会
  • Role of patient reported outcome (PRO) in supporitve/palliateive care trial?
    中島貴子
2018.10 第56回日本癌治療学会学術集会
  • 高齢がん患者の薬物療法における最適なマネージメントを目指して
    中島貴子、土井綾子、堀江良樹
2018 日本消化器病学会北陸支部教育講演会
  • 大腸癌化学療法〜Basic and New〜
    中島貴子
2019.01 第24回日本緩和医療学会学術集会
  • 緩和ケアを希望する患者の臨床的特徴
    櫛野 宣久, 平川 麻美, 藤本 晴美, 沼里 貞子, 古茶 大樹, 月川 賢
2019.02 第91回日本胃癌学会総会
  • Randomized phase II/III study of FL vs. FLTAX in gastric cancer with severe peritoneal metastasis(JCOG1108/WJOG7312G)
    Hiroki Hara, Takako Eguchi Nakajima, Kensei Yamaguchi, Narikazu Boku, Ichinosuke Hyodo, Junki Mizusawa, Tomohiro Nishina, Takeshi Sakamoto, Kohei Shitara, Katsunori Shinozaki, Hiroshi Katayama, Shinichiro Nakamura
  • 最新の胃癌治療戦略〜IOによる変革
    中島貴子
  • 胃癌における免疫療法 最新のエビデンスを実臨床で活かすには
    中島貴子
  • 患者アドボカシーワークショップ
    中島貴子
  • 胃がん治療戦略〜アンメットメディカルニーズにどう対応するか〜
    中島貴子
  • Perspectives of postoperative chemotherapy for gastric cancer: From Asian point of view.
    Takako Eguchi Nakajima
  • Perspectives of postoperative chemotherapy for gastric cancer: From Asian point of view.
    Takako Eguchi Nakajima
2017年度
2017.07 第15回日本臨床腫瘍学会
  • Development of new agents for unresectable gastric cancer: Global?Asian?Japanese?
    Takako Nakajima
  • Clinical Implication of Morphological Changes of Ramucirumab in Metastatic Gastric Cancer
    Naoki Izawa, Hiroyuki Arai, Takuro Mizukami, Yoshiki Horie, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa, Takako Nakajima
  • Early morphologic change (EMC) caused by regorafenib (REGO) in patients (pts) with metastatic colorectal cancer (mCRC)
    Arai H, Miyakawa K, Denda T, Mizukami T, Horie Y, Izawa N, Hirakawa M, Ogura T, Tsuda T, Nakajima TE
  • JACCRO CC-11安全性
    Yu Sunakawa
  • CEA response and DpR (JACCRO CC-05/06)
    Yu Sunakawa
2016年度
2016.07 第14回日本臨床腫瘍学会
  • 口演1-8(日・英) / 大腸がん薬物療法②
    切除不能進行・再発大腸癌に対するサルベージライン化学療法(regorafenib, TAS102)の後方視的検討
    堀江良樹、津田享志、水上拓郎、谷山智子、伊澤直樹、平川麻美、小倉孝氏、中島貴子
  • パネルディスカッション4
    腫瘍内科医はどのようなところで必要とされているのか?(消化器腫瘍内科医の立場)
    中島 貴子
  • パネルディスカッション5
    当院のIO副作用対策チームの取り組み
    中島 貴子、津田 享志
  • イブニングセミナー1
    やさしい大腸がんサルベージライン治療
    中島 貴子
2016.03 第88回日本胃癌学会総会
  • HER2陽性切除不能進行再発胃癌に対するSOX+Trastuzumab併用療法の第II相臨床試験(中間解析)
    高張大亮、若槻尊、石塚直樹、高島淳生、廣中秀一、中島貴子、陳勁松
2015年度
2015.10 第53回 日本癌治療学会
  • 教育講演胃癌
    中島貴子
  • ワークショップ50
    切除不能進行・再発膵癌患者におけるnab-paclitaxel+ Gem療法第I/II相試験:追加解析
    中島貴子
2015.10 第53回日本癌治療学会学術総会 教育セッション11
  • 1. 切除不能・再発胃癌に対する化学療法〜新たなストラテジーとの融合を目指して
    中島貴子
2015.07 第13回 日本臨床腫瘍学会
  • 遠隔転移を有する進行食道扁平上皮癌に対する化学放射線療法の経口摂取改善における臨床的意義
    伊澤直樹、水上拓郎、谷山智子、堀江良樹、平川麻美、小倉孝氏、津田享志、中島貴子
  • T4食道癌の瘻孔形成における臨床経過について
    谷山智子、宮川国久、水上拓郎、堀江良樹、伊澤直樹、平川麻美、小倉孝氏、津田享志、中島貴子
  • EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
    Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakajima TE, Boku N, Nishio K.
  • Fibroblast Growth Factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer
    Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, A. de Velasco M, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima T, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K.
2015.07 Best of ASCO 2015 in Japan
  • 消化器がん (Colorectal Cancer)
    中島貴子
2015.06 第21回 日本緩和治療学会
  • STAT-Jを用いた当院緩和ケアチーム活動の検討
    平川麻美、西木戸修、丸田智子、土屋恭子、吉田彩子、熱方智和子、岸本真希子、穴井己理子、梯紋子、鈴木直、中島貴子
2015.03 第87回 日本胃癌学会
  • 胃癌治療に対する治療開発における日本の役割:内科の視点
    朴 成和
  • 消化器神経内分泌腫瘍の薬物療法
    朴 成和
2014年度
2014.08 第52回 日本癌治療学会
  • コンセンサスミーティング2-1-2 経口抗がん剤(CQ3)、シスプラチン分割(CQ10)の制吐療法、5-HT3受容体拮抗剤(CQ6)
    朴 成和
  • 現在の胃癌薬物療法 -改訂版胃癌治療ガイドラインを中心に-
    朴 成和
  • 切除不能進行再発大腸癌の治療戦略
    朴 成和
2014.07 第12回 日本臨床腫瘍学会
  • Systemic chemotherapy for neucoendocrine carcinoma of the gastrointestinal tract
    Boku N
  • がん患者の看取る場所についての検討:在宅診療に移行した患者が、病院に再入院する理由を中心に
    津田享志、丹下みつる、水上拓郎、谷山智子、伊澤直樹、堀江良樹、平川麻美、中島貴子、朴 成和
  • N2c,N3または鎖骨上窩リンパ節転移を伴うN2bを有する局所進行頭頸部扁平上皮癌に対するTPF導入化学療法
    伊澤直樹、小野澤祐輔、彦坂ともみ、濱内諭、小川洋史、福家智仁、飯田善幸、上條朋之、鬼塚哲郎、横田知哉
2014.06 第19回 日本緩和治療学会
  • STAT-Jを用いた当院緩和ケアチーム活動の検討
    津田享志、西木戸修、鈴木直、岡本真理子、吉田彩子、丸田智子、藤本晴美、湊川紘子、桑島規夫、梯紋子、朴成和
2014.03 第86回 日本胃癌学会
  • Future perspective of Japan-Korea collaboration trials Future perspective of oncologic trials
    Boku N
  • 消化器神経内分泌腫瘍の薬物療法
    朴 成和

学会発表(国際学会)

2019年度
2019.05 American Society Clinical Oncology
  • Clinical verification of circulating tumor RNA (ctRNA) as novel pre-treatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): a biomarker study of the DEEPER trial.
    Yu Sunakawa, Joshua L. Usher, Yolanda S Jaimes, Akihito Tsuji, Manabu Shiozawa, Takanori Watanabe, Hironaga Satake, Hirofumi Ota, Mitsugu Kochi, Hisatsugu Ohori, Dai Manaka, Masato Matsuura, Masahiro Takeuchi, Peter V. Danenberg, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz, Kathleen Danenberg.
  • Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.
    Wataru Okamoto, Yoshiaki Nakamura, Manabu Shiozawa, Yoshito Komatsu, Tadamichi Denda, Hiroki Hara, Yoshinori Kagawa, Yukiya Narita, Hisato Kawakami, Taito Esaki, Tomohiro Nishina, Naoki Izawa, Koji Ando, Toshikazu Moriwaki, Takeshi Kato, Fumio Nagashima, Taroh Satoh, Shogo Nomura, Takayuki Yoshino, Kiwamu Akagi.
  • Genomic Alterations After EGFR Blockade in Patients with RAS Wild-Type Metastatic Colorectal Cancer: Combined Tissue and Blood-Based Analysis from SCRUM-Japan GI-SCREEN and GOZILA.
    Yoshiaki Nakamura, Riu Yamashita, Wataru Okamoto, Yukiya Narita, Yoshito Komatsu, Yoshinori Kagawa, Naoki Takahashi, Taito Esaki, Takeshi Kato, Yu Sunakawa, Tadamichi Denda, Tomohiro Nishina, Atsuo Takashima, Takaaki Kobayashi, Manabu Shiozawa, Eiji Oki, Taroh Satoh, Yuta Adachi, Justin Odegaard, Takayuki Yoshino.
  • Phase I Safety and Pharmacokinetic Study of KN035, the first subcutaneously administered, novel fusion Anti-PD-L1 Antibody in Japanese Patients with Advanced Solid Tumors.
    Toshio Shimizu , Takako Eguchi Nakajima, Ni Lu, Shilin Xue, Wenlian Xu, Amanda Fu, Walt Cao, Haolan Lu, David Liu, Ruiping Dong, Xiaoxiao Wang, Pilin Wang, Danming Zhu, Ting Xu , John Gongo.
2019.06 MASCC
  • Phase III Study of Comparing Dexamethasone on Day 1 with Day 1-4 with Combined Nurokinin-1 Receptor Antagonist, Palonosetron and Olanzapine in Cisplatin-based Chemotherapy:SPARED Trial.
    H. Minatogawa, N. Izawa, T. Kawaguchi, T. Miyaji, A. Yokomizo, Y. Horie, K. Shimomura, K. Honda, H. Morita, N. Hida, A. Tsuboya, T. Tsuda, H. Iihara, Y. Ohno, T. Yamaguchi, T. Nakajima.
2019.07 ESMO-GI
  • Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer.
    Shigenori Kadowaki, Naoki Izawa, Keiko Minashi, Tomohiro Nishina, Takeharu Yamanaka, Kei Muro, Yu Sunakawa, Shuichi Hironaka, Takeshi Kajiwara , Yutaka Kawakami, Takako Eguchi Nakajima.
  • RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC).
    Y Sunakawa, M Nakamura, M Ishizaki, M Kataoka, H Satake, M Kitazono, H Yanagisawa, Y Kawamoto, H Kuramochi, H Ohori, M Nakamura, K Takahashi, F Maeda, C Komeno, M Takeuchi, M Fujii, T Yoshino, W Ichikawa, A Tsuji.
2019.09 CSCO
  • KN.
    Toshio Shimizu , Takako EguchiNakajima, Ni Lu, Qiong Hua, Shilin Xue, Wenlian Xu, Amanda Fu, Walt Cao, Haolan Lu, David Liu, John Gong, Xiaoxiao Wang, Pilin Wang, Danming Zhu, Ting Xu.
2019.09 ESMO Congress
  • Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.
    H Hasegawa, H Taniguchi, T Kato, S Fujii, H Ebi, M Shiozawa, S Yuki, T Masuishi, K Kato, N Izawa, T Moriwaki, Y Kagawa, Y Sakamoto, W Okamoto, Y Nakamura, K Yamazaki, T Yoshino.
  • Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial).
    Y. Sunakawa, Y. Takahashi, E. Inoue, Y. Sakamoto, R. Kawabata, H. Yabusaki, J.Matsuyama, A. Ishiguro, M. Takahashi, Y. Akamaru, Y. Kito, A. Makiyama, H.Yasui, H. Kawakami, T. Nakajima, K. Muro, R. Matoba, W. Ichikawa, M.Fujii.
  • Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study.
    Y. Kawamoto, Y. Nakamura, M. Ikeda, H. Bando, T. Esaki, M. Ueno, T. Nishina, Y. Kagawa, E. Oki, T. Denda, T. Mizukami, N. Takahashi, N. Okano, I. Miki, Y. Sakamoto, M. Lefterova, J. Odegaard, H. Taniguchi, C. Morizane, T. Yoshino.
2020.01 ASCO-GI
  • A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer.
    Shuichi Hironaka, Shigenori Kadowaki, Naoki Izawa, Tomohiro Nishina, Takeharu Yamanaka, Keiko Minashi, Kei Muro, Yu Sunakawa, Takeshi Kajiwara, Yuichiro Hayashi, Yutaka Kawakami, Takako Eguchi Nakajima.
  • The treatment strategy of the second-line chemotherapy for metastatic colorectal cancer (mCRC) patients (pts) with early progression in the first-line chemotherapy with bevacizumab (BEV), BEV beyond progression (BBP), or non-BBP.
    Takeshi Kawakami, Shun Yamamoto, Seiichiro Mitani, Taito Esaki, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama, Kentaro Yamazaki, Toshiki Masuishi, Takako Eguchi Nakajima, Hiroyuki Okuda, Toshikazu Moriwaki, Narikazu Boku.
  • RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC).
    Yu Sunakawa, Masato Nakamura, Masahiro Ishizaki, Masato Kataoka, Hironaga Satake, Masaki Kitazono, Hideyuki Yanagisawa, Yasuyuki Kawamoto, Hidekazu Kuramochi, Hisatsugu Ohori, Michio Nakamura, Fumiyo Maeda, Chihiro Komeno, Masahiro Takeuchi, Masashi Fujii, Takayuki Yoshino, Wataru Ichikawa, Akihito Tsuji.
  • Plasma VEGF-D and PlGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study.
    Hiroya Taniguchi, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina, Yoshinori Kagawa, Naoki Takahashi, Hisateru Yasui, Tadamichi Denda, Yu Sunakawa, Kentaro Yamazaki, Taito Esaki, Hisato Kawakami, Takeshi Kato, Kazuhiro Yoshida, Atsuo Takashima, Hiroko Ohmiya, Shogo Nomura, Atsushi Ohtsu, Takayuki Yoshino.
  • Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.
    Yoshiaki Nakamura, Hiroya Taniguchi, Hideaki Bando, Ken Kato, Taito Esaki, Yoshito Komatsu, Naoki Takahashi, Makoto Ueno, Yoshinori Kagawa, Tomohiro Nishina, Takeshi Kato, Yoshiyuki Yamamoto, Junji Furuse, Tadamichi Denda, Hisato Kawakami, Eiji Oki, Yu Sunakawa, Taroh Satoh, Takayuki Yoshino, Atsushi Ohtsu.
  • Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial.
    Naoki Izawa, Kohei Shitara, Toshiki Masuishi, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Hiroyuki Okuda, Chihiro Kondoh, Tomohiro Nishina, Akitaka Makiyama, Hideo Baba, Hironori Yamaguchi, Masato Nakamura, Akihito Tsuji, Taito Esaki, Yoshinori Miyata, Masahito Kotaka, Takeharu Yamanaka, Takako Eguchi Nakajima, Kei Muro.
  • Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial.
    Naoki Izawa, Kohei Shitara, Toshiki Masuishi, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Hiroyuki Okuda, Chihiro Kondoh, Tomohiro Nishina, Akitaka Makiyama, Hideo Baba, Hironori Yamaguchi, Masato Nakamura, Yu Sunakawa, Kohei Akiyoshi, Mikio Sato, Kimio Yonesaka, Takayuki Yoshino, Takeharu Yamanaka, Kei Muro.
2018年度
2018.04 American Association for Cancer Reasearch
  • Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer
    Takako Eguchi Nakajima, Narikazu Boku, Hiroyuki Arai, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa.
2018.06 American Society Clinical Oncology
  • Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: JACCRO CC-11.
    Yu Sunakawa, Hironaga Satake, Joshua L. Usher, Yolanda S Jaimes, Yuji Miyamoto, Masato Nakamura, Hiroshi Nakayama, Nobuhiro Sugano, Akinori Takagane, Masahiro Gotoh, Takanori Watanabe, Kiyoshi Ishigure, Chihiro Tanaka, Masahiro Takeuchi, Masashi Fujii, KATHLEEN DANENBERG, Heinz-Josef Lenz, Takashi Sekikawa, Wataru Ichikawa.
2018.10 European Society for Medical Oncology
  • Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer
    Y. Sunakawa, H. Arai, N. Izawa, T. Mizukami, Y. Horie, A. Doi, M. Hirakawa, T. Ogura, T. Tsuda, T.E. Nakajima.
  • Gene mutation status in circulating tumor DNA (ctDNA) and 1st-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation
    Y. Sunakawa, J. Usher, H. Satake, Y. Jaimes, Y. Miyamoto, M. Nakamura, M. Kataoka, M. Shiozawa, A. Takagane, T. Terazawa, T. Watanabe, K. Ishigure, C. Tanaka, T. Sekikawa, M. Takeuchi, M. Fujii, K. Danenberg, P.V. Danenberg, H.J. Lenz, W. Ichikawa.
  • A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3
    Y. Sunakawa, S. Stintzing, S. Cao, J. Luecke, D. Thompson, M. Moran, S.H. Astrow, J. Hsiang, C. Stephens, W. Zhang, A. Tsuji, T. Takahashi, T. Denda, K. Shimada, M. Kochi, M. Takeuchi, M. Fujii, W. Ichikawa, V. Heinemann, H.J. Lenz.
  • Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer
    T. Mizukami, Y. Sunakawa, H. Arai, M. Chosokabe, A. Doi, Y. Horie, M. Hirakawa, O. Saji, S. Naruki, N. Izawa, T. Ogura, T. Tsuda, T. Enomoto, S. Mikami, T. Fujino, T. Otsubo, T. Nakajima.
2018.11 ESMO-ASIA
  • Case presentation Metastatic oeso-gastric cancer WHY we need an Asian guideline for oeso-gastric cancer?
    Takako Eguchi Nakajima.
2018.12 ESMO-Immuno
  • A translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial)
    Y. Sunakawa, K. Muro, T.E. Nakajima, H. Kawakami, E. Inoue, R. Matoba, Y. Sato, W. Ichikawa, M. Fujii.
2019.01 ASCO-GI
  • Prospective evaluation of a developed S-1 dosage formula based on renal function.
    Takuro Mizukami, Masashi Takeuchi, Chiyo K. Imamura, Eisuke Booka, HIROYA TAKEUCHI, Takeshi Kawakami, Taro Funakoshi, Kazushige Wakuda, Yu Aoki, Yasuo Hamamoto, Minoru Kitago, Hirofumi Kawakubo, Narikazu Boku, Yusuke Tanigawara, Yuko Kitagawa.
  • Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN
    Takuro Mizukami, Masaki Takahashi, Yu Sunakawa, Satoshi Yuki, Yoshinori Kagawa, Atsuo Takashima, Kyoko Kato, Hiroki Hara, Tadamichi Denda, Toshikazu Moriwaki, Manabu Shiozawa, Eiji Oki, Taroh Satoh, Hisato Kawakami, Taito Esaki, Tomohiro Nishina, Wataru Okamoto, Takayuki Yoshino, Takako Eguchi Nakajima.
  • Randomized phase II/III study of 5-fluorouracil /l-leucovorin vs. 5-fluorouracil /l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G). American Society of Clinical Oncology, Gastrointestinal Cancer Symposium 2019 poster presentation
    Kensei Yamaguchi, Takako Eguchi Nakajima, Narikazu Boku, Ichinosuke Hyodo4 Junki Mizusawa, Hiroki Hara, Tomohiro Nishina, Takeshi Sakamoto, Kohei Shitara, Katsunori Shinozaki, Hiroshi Katayama, Shinichiro Nakamura.
  • CEA response at 4 wks as an early predictor for outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with 1st-line cetuximab-based chemotherapy: a STEP-analysis in the JACCRO CC-05/06 trials.
    Yu Sunakawa, Xuemin Fang, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Toshiki Masuishi, Masahiro Tsuda, Tatsuya Okuno, Takao Tamura, Kaoru Furushima, Hidekazu Kuramochi, Junichi Koike, Yutaka Yonemura, Hisateru Yasui, Masahiro Takeuchi, Masashi Fujii, Wataru Ichikawa.
2017年度
2017.04 American Association for Cancer Reasearch
  • Identification of a FGFR3-TACC3 fusion in esophageal cancer
    T. Mizukami, K. Sakai, S. Naruki, T. Taniyama, Y. Horie, N. Izawa, T. Tsuda, T. Fujino, N. Boku, H. Yasuda, T. Fukunaga, T. Eguchi Nakajima, K. Nishio.
2017.06 Multinational Association of Supportive Care in Cancer
  • What are the barriers to and facilitators for the implementation of early palliative care in Japan?
    Takako Eguchi Nakajima.
2017.09 European Society for Medical Oncology
  • Dynamic changes in levels of gene mutations using circulating DNA and efficacy of 1st-line modified FOLFOXIRI plus bevacizumab for metastatic colorectal cancer harboring RAS mutation (JACCRO CC-11)
    Y. Sunakawa, T. Sekikawa, J. Usher, H. Satake, Y. James, Y. Miyamoto, M. Nakamura, K. Kazama, A. Takagane, A. Makiyama, K. Kobayashi, Y. Kubota, M. Mori, M. Kotaka, M. Takeuchi, M. Fujii, K. Danenberg, H. Lenz, W. Ichikawa.
2018.01 ASCO-GI
  • Fluoropyrimidine (F) alone versus F plus platinum (P) as 1st-line chemotherapy in patients (pts) with advanced gastric cancer (AGC) and severe peritoneal metastasis (SPM): A multicenter observational study.
    Hiroyuki Arai, Satoru Iwasa, Narikazu Boku, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Shuichi Hironaka, Naoki Fukuda, Daisuke Takahari, Takako Eguchi Nakajima.
  • Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: JACCRO CC-11.
    Yu Sunakawa, Hironaga Satake, Joshua L. Usher, Yolanda S Jaimes, Yuji Miyamoto, Masato Nakamura, Hiroshi Nakayama, Nobuhiro Sugano, Akinori Takagane, Masahiro Gotoh, Takanori Watanabe, Kiyoshi Ishigure, Chihiro Tanaka, Masahiro Takeuchi, Masashi Fujii, KATHLEEN DANENBERG, Heinz-Josef Lenz.
2016年度
  • The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and Cancer-Related Genome Alterations in advanced colorectal cancer (CRC) (GI-SCREEN 2013-01-CRC sub-study).
    American Society of Clinical Oncology 2016, poster presentation #3573
    Takeshi Kajiwara, Kohei Shitara, Tadamichi Denda, Satoshi Yuki, Takao Tamura, Kenta Kawasaki, Eiji Shinozaki, Takako E. Nakajima, Atsuo Takashima, Kiwamu Akagi,Taito Esaki, Daisuke Naruge, Toshihiro Kudo, Hiroya Taniguchi, Hiromichi Ebi, Toshikazu Moriwaki, Satoshi Fujii, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino.
  • Phase III study comparing dexamethasone on day1 to on day1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.
    American Society of Clinical Oncology 2016, Poster Discussion #10019
    Kunihiro Mathuzaki, Mamoru Fukuda, Yuka Ito, Kentaro Sakamaki, Masahiko Ando, Yasuyuki Kojima, Naoki Furuya, Takashi Tsuda,Hiroko Minatogawa, Yasushi Ichikawa, Ichiro Ohta, Saori Takei, Yutaka Tokuda, Kazutaka Narui, Ayako Tsuboya,Takasi Suda,Satoshi Morita,Takeharu Yamanaka, Narikazu Boku, Takako Eguchi Nakajima.
2015年度
2015.09 39th European Society for Medical Oncology
  • ORAL presentation #1504
    Impact of worsening in patient reported symptomatic adverse events (AEs) on deterioration of daily assessed quality of life (QOL) in cancer patients receiving initial chemotherapy; prospective exploratory study
    Horie Y, Mori K, Kyomori C, Izawa N, Taniyama T, Hirakawa M, Ogura T, Tsuda T, Nakajima T, Boku N.
  • poster presentation #259
    Fibroblast growth factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer
    Mizukami T, Togashi Y, Banno E, Terashima M, A. de Velasco M, Sakai K, Hayashi H, FujitaY, Tomida S, Nakajima T, Boku N, Ito A, Nakagawa K, Nishio K.
  • poster presentation #2339
    Randomized phase II study of S-1 plus oral leucovorin (SL) versus SL plus oxaliplatin (SOL) versus S-1 plus cisplatin (SP) in patients with advanced gastric cancer (AGC): Update data.
    Y. Komatsu, H. Shuichi, S. Naotoshi, Y. Kensei, M. Toshikazu, N. Tomohiro, T. Akihito, E.N. Takako, G. Masahiro, M. Nozomu, B. Hideaki, E. Taito, E. Yasunori, S. Takashi, M. Shigemi, B. Narikazu, B. Hideo, H. Ichinosuke.
2015.06 50th American Society Clinical Oncology
  • A phase 2 randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in patients with cancer pain
    Boku N, Fujita S, Oda K, Tauchi K, Nakata K, Shinozaki K, Okuno M, Kawai Y, Kikukawa H, Suzuki R, Nakazawa H, Kojima H, Mizutani M, Hara T, Yokota T, Suzuki Y, Narabayashi M.
2015.04 106th American Association for Cancer Reasearch
  • Fibroblast Growth Factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer.
    Mizukami T, Togashi Y, Banno E, Terashima M, A. de Velasco M, Sakai K, Hayashi H, FujitaY, Tomida S, Nakajima T, Boku N, Ito A, Nakagawa K, Nishio K.
2014年度
2014.04 105th American Association for Cancer Reasearch
  • Predictive signature of response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer cells by tyrosine kinase activity profiling
    Izawa N, Serizawa M, Naji F, de Wijn R, Hilhorst R, Ruijtenbeek R, Yasui H, Boku n, Koh Y.

論文業績(和文)

2019年度

《原著・総説・解説》

1. 腫瘍内科医に必要な緩和医療のポイント
  • 臨床腫瘍プラクティス, 15(3).
  • 土井綾子
2. 肝機能障害への対応
  • がん免疫療法, 3(1):24-26,2019.
  • 新井裕之, 中島貴子
3. 後方ライン治療におけるICのポイント
  • 大腸癌に対するレゴラフェニブ治療,80-84,2019.
  • 新井裕之, 中島貴子
4. がん治療におけるPatient-Reported Outcome
  • 腫瘍内科,2019;25(1).78-83.
  • 土井綾子、堀江良樹、中島貴子
2018年度

《原著・総説・解説》

1. 抗体薬 ラムシルマブ、アフリベルセプト
  • 腫瘍内科, 21(6): 646-653, 2018.
  • 伊澤直樹, 中島貴子
2. 胃癌化学療法におけるチーム医療の取り組み
  • 日本消化器病学会雑誌, 115(6): 521-528, 2018.
  • 伊澤直樹, 中島貴子
3. ASCOレポート、HIPEC・WJOG7112G(beyond Tmab)
  • 消化器病広場, 2018.
  • 伊澤直樹
4. nab-PTX/RAM
  • 消化器癌化学療法レジメンハンドブック, 2018.
  • 伊澤直樹
5. がん化学療法の薬はや調べノート2019・2020年版
  • がんナーシング2019年別冊, 2018.
  • 新井裕之, 伊澤直樹, 小倉孝氏, 中島貴子
6. DNAミスマッチ修復欠損またはMSI-highと免疫チェックポイント阻害薬効果の相関
  • がん分子標的治療, 16(2): 94-97, 2018.
  • 砂川 優
7. クリニカルシークエンスを基にした分子標的治療の展開
  • 病理と臨床, 36(7): 676-680, 2018.
  • 水上拓郎, 砂川優, 中島貴子
8. Pan-Asian adapted ESMO consensus guidelineの概要
  • 腫瘍内科, 22(1): 2-8, 2018.
  • 水上拓郎, 中島貴子
9. 大腸がんに対する臨床開発と方向性
  • 腫瘍内科, 22(1): 45-53, 2018.
  • 砂川 優
10. 胃癌・RAM(単剤, RAM+PTX)
  • エビデンスに基づいた癌化学療法ハンドブック2018, 318-320, 2018.
  • 新井裕之, 中島貴子
11. 薬物療法によってフレイル状態に陥りやすい高齢がん患者への対応
  • 臨床腫瘍プラクティス, 14(4): 249-254, 2018.
  • 土井綾子, 堀江良樹, 中島貴子
12. 疾患別に学ぼう! 9消化器癌
  • ヘルスケアプロバイダのためのがん生殖医療, 2018.
  • 小倉孝氏
13. 消化器外科専門医の心得
  • 消化器外科専門医の心得, 2018.
  • 伊澤直樹
14. 消化器(口内炎、食欲不振、悪心嘔吐、下痢脱水)
  • 消化器がん化学療法副作用マネジメント, 2018.
  • 土井綾子, 堀江良樹, 中島貴子
15. GI Cancer Selected Papers
  • GI Cancer Cutting Edge, 2018.
  • 伊澤直樹
16. 分子標的薬の最適な治療シークエンス:大腸がん
  • がん分子標的治療, 2018.
  • 伊澤直樹
17. 後方ライン治療におけるICのポイント
  • 大腸癌に対するレゴラフェニブ治療, 80-84, 2019.
  • 新井裕之
18. dMMR/MSI-H大腸がんの治療
  • 癌と化学療法, 45(11): 1602-1607, 2018.
  • 砂川 優
19. 肝機能障害への対応
  • がん免疫療法, 2018.
  • 新井裕之
20. 抗EGFR抗体薬使用後の薬剤耐性クローンの指数関数的減少:抗EGFR抗体薬のre-challengeへの影響
  • 消化器病広場, 2019.
  • 伊澤直樹
21. 腫瘍内科医に必要な緩和医療のポイント
  • 臨床腫瘍プラクティス, 2019.
  • 土井綾子
2017年度

《原著・総説・解説》

1. StageⅣ大腸癌に対する治療戦略:日本と欧米の比較
  • 臨床消化器内科6月増刊号, 32(7): 182-187, 2017.
  • 濱良太, 新井裕之, 中島貴子
2. GOLD試験(胃がん2次治療におけるweekly paclitaxel±olaparib
  • がん分子標的治療, 15(2): 212-215, 2017.
  • 伊澤直樹, 中島貴子
3. 化学療法のレジメン講座
  • レジメン, 15(2): 212-215, 2017.
  • 伊澤直樹, 中島貴子
4. 胃癌RAM (単剤、PTX+RAM)
  • エビデンスに基づいた癌化学療法ハンドブック2017, 295-297, 2017.
  • 新井裕之, 中島貴子
5. 多遺伝子アッセイを用いた結腸がん術後再発リスク予測の可能性―SUNRISE試験の結果から
  • がん分子標的治療, 15(2) 2017.
  • 水上拓郎
6. JCOG1108/WJOG7312G高度腹水を伴うまたは経口摂取不能の腹膜転移を有する胃癌に対する5-FU/l-LV療法 vs FLTAX (5-FU/l-LV/PTX)療法のランダム化第II/III相比較試験
  • 胃がんperspective, 9(2): 60-63, 2017.
  • 中島貴子
7. 大腸がんに対する臨床開発と方向性
  • 腫瘍内科, 20(1): 19-27, 2017.
  • 砂川 優
8. 進行大腸がんにおいて原発部位が左側の患者では生存期間が長い
  • がんサポート7月, 2017.
  • 砂川 優
9. 切除不能・再発進行胃がんの治療戦略 state-of-art
  • 腫瘍内科, 20(1): 28-35, 2017.
  • 新井裕之, 中島貴子
10. 抗EFGR抗体薬を使うべき症例、ひとまず様子をみるべき症例
  • 臨床腫瘍プラクティス, 13(3): 181-188, 2017.
  • 砂川 優
11. ①進行大腸がんの一次治療でFOLFOXIRI療法を用いる場合の注意点、②大腸癌の分子標的治療薬の作用機序の違いを考慮した治療戦略の進め方、③分子標的治療に伴う有害事象とその対応 (骨髄抑制、発熱性好中球減少症)
  • 進行・再発大腸癌の分子標的治療, 18,46,93-98, 2017.
  • 新井裕之, 中島貴子
12.免疫チェックポイント阻害薬 副作用対策チームの実践
  • 薬事, 59: 2449-2454, 2017.
  • 塩川尚恵, 津田享志, 中島貴子
13.「胃がん」Topic Q & A
  • Cancer Board, 3(3): 460-471, 2017.
  • 伊澤直樹
14.膵がんにおけるFOLFIRINOX療法の試験
  • がん分子標的治療, 15(4): 82-86, 2017.
  • 砂川 優
15.がん患者の終末期医療における看取り場所の聴取後の在宅がん緩和医療移行の実態
  • ホスピスケアと在宅ケア, 25(2): 88-95, 2017.
  • 津田享志, 平川麻美, 丹下みつる,保科かおり, 新井裕之, 濵良太, 水上拓郎, 伊澤直樹, 堀江良樹, 小倉孝氏, 朴 成和, 中島貴子
16.RIASE試験におけるramucirumabの効果予測バイオーカーの検討
  • 消化器病広場, 60(4), 2017.
  • 伊澤直樹
17.切除不能進行・再発胃癌に対する1次治療について
  • 特集 胃癌, 76(3): 469-475, 2017.
  • 伊澤直樹, 中島貴子
18.院内システムの運用による多職種連携
  • オンコロジーエマージェンシー, 60(4): 688-691, 2017.
  • 横溝綾子, 伊澤直樹
2016年度

《原著・総説・解説》

1. 食道癌
  • 薬局, 67: 1383-1386, 2016.3.
  • 谷山智子, 朴 成和
2. 胃癌
  • 薬局, 67: 1389-1392, 2016.3.
  • 堀江良樹, 朴 成和
3. 大腸癌
  • 薬局, 67: 1393-1400, 2016.3.
  • 伊澤直樹, 朴 成和
4. 胃がん 1) ファーストラインの選択 (S-1+CDDP療法のエビデンスと実際)
  • うまく続ける!消化管がん薬物療法の基本とコツ, 45-51, 2016.4.
  • 中島貴子
5. 食道がん、胃がん、大腸がんに対するimmune checkpoint阻害薬の開発状況
  • 腫瘍内科 17(1): 45-50, 2016.
  • 津田享志、中島貴子
6. 消化管神経内分泌腫瘍の薬物療法 新たな展開
  • 腫瘍内科 2016; 17 (2): 213-219.
  • 伊澤直樹, 中島貴子
7. 胃がん:切除不能・再発. 日本メディカルセンター 消化器がん化学療法
  • 臨床消化器内科6月増刊号 31(7): 182-188, 2016
  • 堀江良樹、中島貴子
8. 精密医療を目指した胃がんに対する殺細胞性抗悪性腫瘍薬・分子標的治療薬
  • 腫瘍内科 17 (5): 493-499, 2016.
  • 水上拓郎、津田享志、中島貴子
9. 切除不能・再発胃がんの新薬・バイオマーカー開発の現状と展望
  • Mebio 33 (7): 12-18, 2016.
  • 水上拓郎、小倉孝氏、中島貴子
2015年度

《原著・総説・解説》

1. 副作用別対策「皮膚障害・手足症候群」
  • がん分子標的治療, 13, 2015.1.
  • 堀江良樹, 中島貴子
2. 胃がん、切除不能再発
  • 臨牀消化器内科, 31, 2015.2.
  • 堀江良樹, 中島貴子
3. 経口抗がん薬に関する治療戦略と時流
  • がん看護, 20, 2015.2.
  • 堀江良樹, 中島貴子
4. 患者さんへの説明・インフォームドコンセントの基本
  • 消化器がん化学療法の実践, 改訂版: 20-24, 2015.3.
  • 谷山智子, 中島貴子
5. 手足症候群・皮膚障害のマネジメント
  • がんを見る, 52: 517-521, 2015.3.
  • 伊澤直樹, 中島貴子
6. 化学療法と内視鏡の接点
  • 食道・胃ESD, 改訂版: 28, 2015.3.
  • 朴 成和
7. 大腸癌化学療法剤有害事象の特徴
  • 最新臨床大腸学, 73: 598-603, 2015.4.
  • 伊澤直樹, 中島貴子
8. がん分子標的がん治療
  • Pharm Tech Japan, 31: 107-118, 2015.5.
  • 伊澤直樹, 朴成和, 伊東文生
9. 進行・再発胃がんに新しい治療法 着実に広がる治療の選択肢
  • がんサポート, 148: 44-47, 2015.7.
  • 朴 成和
10. 胃がんにおけるrilotumumabのランダム化第Ⅱ相臨床試験とRilomet試験の失敗
  • がん分子標的治療, 13: 91-93, 2015.8.
  • 伊澤直樹, 中島貴子
11. 胃がんに対する分子標的治療
  • 細胞, 47: 517-521, 2015.8.
  • 伊澤直樹, 中島貴子
12. Pharmacogenomics and biomarker; FGFR阻害薬のバイオマーカー
  • がん分子標的治療, 13: 65-70, 2015.9.
  • 水上拓郎, 西尾和人
13. 分子標的薬を用いた個別化治療に必要なバイオマーカー
  • インフォームドコンセントのための図説シリーズ, 改訂版: 151-157, 2015. 10.
  • 伊澤直樹, 中島貴子
14. 手足症候群・皮膚障害のマネジメント
  • medicina 特集 がんを診る 一般内科医が知っていおくべきがん薬物療法のマネジメント 2015; 52: 517-521.
  • 伊澤直樹, 中島貴子
15. 切除不能進行・再発胃がんに対する一次治療選択の仕方
  • 腫瘍内科 16(4): 312-316, 2015.
  • 堀江良樹、中島貴子
2014年度

《原著・総説・解説》

1. 胃がん 悪性腫瘍
  • medicina, 51: 106-108, 2014.1.
  • 谷山智子, 朴 成和
2. 食道癌・胃癌の最新のエビデンスと注目すべき進行中の臨床試験について
  • Bio Clinica, 29: 19-21, 2014.2.
  • 津田享志, 朴 成和
3. 胃癌の治療戦略 化学療法 一次治療、二次治療のレジメン選択
  • 最新胃癌学, 72: 445-452, 2014.1.
  • 水上拓郎, 中島貴子
4. Pharmacoethnic difference
  • 最新胃癌学, 72: 693-696, 2014.1.
  • 朴 成和
5. スキルス胃がん
  • 最新がん薬物療法学, 72: 369-372, 2014.2.
  • 谷山智子, 中島貴子
6. 腫瘍内科医からみた消化器癌術前化学療法
  • 消化器外科, 37: 409-415, 2014.4.7.
  • 津田享, 朴 成和
7. 抗EGFR抗体薬の副作用、マネジメントの実際
  • 消化器がんPractical Treatment, 60-63, 2014.7.
  • 津田享志, 中島貴子
8. 胃がんに対する分子標的薬開発の成否からの教訓
  • がん分子標的治療, 12: 50-58, 2014.7.
  • 朴 成和, 清水俊雄, 西尾和人, 設楽鉱平
9. ASCO COI policyについて
  • 腫瘍内科, 14: 94-98, 2014.7.
  • 朴 成和
10. 抗VEGF抗体の作用機序
  • 血液内科, 69: 368-374, 2014.9.
  • 谷山智子, 朴 成和
11. 消化器がん診療の新たな展開
  • 内科, 114: 565-570, 2014.10.
  • 伊澤直樹, 朴 成和
12. わが国における大規模無作為化比較試験1 JCOG9912, SPIRITS, GC0301/TOP-002, JACCRO GC-03など
  • オンコロジークリニカルガイド 消化器癌化学療法, 改訂第4版: 90-99, 2014.10.
  • 堀江良樹, 朴 成和
13. がんの薬物療法・緩和医療 大腸癌
  • 消化器病診療, 第2版:435-438, 2014.10.
  • 谷山智子, 朴 成和
14. レジメン+症例 胃癌 nab-PTX
  • 消化器がん化学療法レジメンハンドブック, 2版: 47-50, 2014.10.
  • 伊澤直樹, 安井博史
15. 消化器(口内炎、食欲不振、悪心嘔吐、下痢脱水)
  • 消化器がん化学療法副作用マネジメント, 初版: 216-232, 2014.9.
  • 谷山智子, 中島貴子
16. 副作用と症状マネジメント
  • がん化学療法看護, 初版: 38-39,52-53,58-59, 2014.4.
  • 谷山智子, 中島貴子
17. 胃がん
  • 抗悪性腫瘍薬安全使用ハンドブック, 初版: 451-460, 2014.
  • 伊澤直樹, 中島貴子

論文業績(英文)

《2019年度》

《原著・総説・解説》

1. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
  • Investigational New Drugs. 37(178):1-9, 2019.
  • Takako Eguchi Nakajima, Ayako Doi, Hiroyuki Arai, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa.
2. Multicenter phase II study of trastuzumab with S‑1 plus oxaliplatin for chemotherapy‑naïve, HER2‑positive advanced gastric cancer.
  • Gastric Cancer. 22(96):1-9, 2019.
  • Daisuke Takahari, Keisho Chin, Naoki Ishizuka, Atsuo Takashima, Keiko Minashi, Shigenori Kadowaki, Tomohiro Nishina, Takako Eguchi Nakajima, Kenji Amagai, Nozomu Machida, Masahiro Goto, Keisei Taku, Takeru Wakatsuki, Hirokazu Shoji, Shuichi Hironaka, Narikazu Boku, Kensei Yamaguchi.
3. Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.
  • International Journal of Clinical Oncology. 25(143):1-42, 2019.
  • Yojiro Hashiguchi, Kei Muro, Yutaka Saito, Yoshinori Ito, Yoichi Ajioka, Tetsuya Hamaguchi, Kiyoshi Hasegawa, Kinichi Hotta, Hideyuki Ishida, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Yusuke Kinugasa, Keiko Murofushi, Takako Eguchi Nakajima, Shiro Oka, Toshiaki Tanaka, Hiroya Taniguchi, Akihito Tsuji, Keisuke Uehara, Hideki Ueno, Takeharu Yamanaka, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Michio Itabashi, Kentaro Sakamaki, Keiji Sano, Yasuhiro Shimada, Shinji Tanaka, Hiroyuki Uetake, Shigeki Yamaguchi, Naohiko Yamaguchi, Hirotoshi Kobayashi, Keiji Matsuda, Kenjiro Kotake, Kenichi Sugihara.
4. Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer.
  • Oncology. 97(2):94-101, 2019.
  • Naoki Izawa Yu Sunakawa Ayako Doi Hiroyuki Arai Yoshiki Horie Mami Hirakawa Takuro Mizukami Takashi Ogura Takashi Tsuda Takako Eguchi Nakajima.
5. Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
  • BMC Cancer. 19(1):652, 2019.
  • Hiroyuki Arai, Satoru Iwasa, Narikazu Boku, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Keiko Minashi, Shuichi Hironaka, Naoki Fukuda, Daisuke Takahari and Takako Eguchi Nakajima.
6. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives.
  • Drugs. 79(6):633-645, 2019.
  • 水上拓郎、伊澤直樹、中島貴子、砂川優
7. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
  • Cancer Science. 2019;110(11):3565-3572.
  • Tetsuya Hamaguchi, Tadamichi Denda, Toshihiro Kudo, Naotoshi Sugimoto, Takashi Ura, Kentaro Yamazaki, Hirofumi Fujii, Takeshi Kajiwara, Takako Eguchi Nakajima, Shin Takahashi, Satoshi Otsu, Yoshito Komatsu, Fumio Nagashima, Toshikazu Moriwaki, Taito Esaki, Takeo Sato, Michio Itabashi, Eiji Oki, Toru Sasaki, Marielle Chiron, Takayuki Yoshino.
8. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.
  • ESMO Open. 2019 , 2019;00(00):1-5.
  • Toshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, Hideaki Bando, Yoshito Komatsu, Eiji Shinozaki, Takako Eguchi Nakajima, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Masashi Wakabayashi, Shogo Nomura, Koji Takahashi, Hiromi Ono, Nami Hirano, Noriko Fujishiro, Nozomu Fuse, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino.
9. DELIVER (JACCRO GC-08) Trial: Discover Novel Host-Related Immune-Biomarkers for Nivolumab in Advanced Gastric Cancer
  • Future Oncol. 15(21), 2441-2447.
  • Yu Sunakawa, Eisuke Inoue, Ryo Matoba, Hisato Kawakami, Yoshiharu Sato, Takako Eguchi Nakajima, Kei Muro, Wataru Ichikawa, Masashi Fujii.
10. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
  • Future Oncol. 9 849.
  • Jesús García-Foncillas, Yu Sunakawa, Dan Aderka, Zev Wainberg, Philippe Ronga, Pauline Witzler, Sebastian Stintzing.
11. Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy.
  • Esophagus. 17 (1), 67-73.
  • Taniyama TK, Tsuda T, Miyakawa K, Arai H, Doi A, Hirakawa M, Horie Y, Mizukami T, Izawa N, Ogura T, Sunakawa Y, Nakajima TE..
12. Randomized phase II/III study of 5‑fluorouracil/l‑leucovorin versus 5‑fluorouracil/l‑leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
  • Gastric Cancer.
  • Takako Eguchi Nakajima, Kensei Yamaguchi, Narikazu Boku, Ichinosuke Hyodo, Junki Mizusawa, Hiroki Hara, Tomohiro Nishina, Takeshi Sakamoto, Kohei Shitara, Katsunori Shinozaki, Hiroshi Katayama, Shinichiro Nakamura, Kei Muro, Masanori Terashima.
13. Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients.
  • Clin Pharmacol Ther.
  • Yutaro Kubota, Ken-Ichi Fujita, Takehiro Takahashi, Yu Sunakawa, Hiroo Ishida, Kazuyuki Hamada, Wataru Ichikawa, Takuya Tsunoda, Kazuhiro Shimada, Yusuke Masuo, Yukio Kato, Yasutsuna Sasaki.
《2018年度》

《原著・総説》

1. Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.
  • Pharmacogenomics J. 18(2): 262-269, 2018.
  • Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ.
2. A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
  • Oncotarget. 9: 18811-18820, 2018.
  • Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, Masato Nakamura, Hiroshi Nakayama, Manabu Shiozawa, Akitaka Makiyama, Kazuma Kobayashi, Yutaro Kubota, Misuzu Mori, Masahito Kotaka, Akinori Takagane, Masahiro Gotoh, Masahiro Takeuchi, Masashi Fujii, Wararu Ichikawa and Takashi Sekikawa.
3. Reply to L. Celio et al.
  • J Clin Oncol. 78, 2018.
  • Yuka Ito, Takashi Tsuda, Kentaro Sakamaki, Takako Eguchi Nakajima.
4. Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy.
  • Clinical Journal of Gastroenterology. 11(6): 487-492, 2018.
  • Ryuta Shigefuku, Tsunamasa Watanabe, Takuro Mizukami, Kotaro Matsunaga, Nobuhiro Hattori, Takuya Ehira, Tatsuya Suzuki, Hiroyasu Nakano, Yoshinori Sato, Yasumasa Matsuo, Kazunari Nakahara, Hiroki Ikeda, Nobuyuki Matsumoto, Takashi Tsuda, Masafumi Katayama, Satoshi Koizumi, Chiaki Okuse, Michihiro Suzuki, Takehito Otsubo, Takako Eguchi Nakajima, Hiroshi Yasuda, Fumio Itoh.
5. Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.
  • ESMO Open. 3(5), 2018.
  • Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, Takako Eguchi-Nakajima, Hiroya Taniguchi, Satoshi Morita, Naruhito Takenaka, Daisuke Ozawa, Kuniaki Shirao.
6. Immune-related genes to dominate neutrophil-lymphocyte ratio (NLR) associated with survival of cetuximab treatment in metastatic colorectal cancer.
  • Clinical Colorectal Cancer, 2018.
  • Yu Sunakawa, Dongyun Yang, Shu Cao, Wu Zhang, Miriana Moran, Stephanie H. Astrow, Jack Hsiang, Craig Stephens, Akihito Tsuji, Takehiro Takahashi, Hiroaki Tanioka, Yuji Negoro, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Tetsuya Eto, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz.
7. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).
  • Gastric Cancer, 2018.
  • Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N.
8. Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer.
  • Molecular Cancer Therapeutics, 2018.
  • Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W.
9. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology 30: 34–43, 2019 doi:10.1093/annonc/mdy498.
  • Annals of Oncology, 30(1): 34-43, 2019.
  • K. Muro, F. Lordick, T. Tsushima, G. Pentheroudakis, E. Baba, Z. Lu, B. C. Cho, I. M. Nor, M. Ng, L.-T. Chen, K. Kato, J. Li, M.-H. Ryu, W. I. Wan Zamaniah, W.-P. Yong, K.-H. Yeh, T. E. Nakajima, K. Shitara, H. Kawakami, Y. Narita, T. Yoshino, E. Van Cutsem, E. Martinelli, E. C. Smyth, D. Arnold, H. Minami, J. Tabernero & J.-Y. Douillard.
10. Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.
  • Annals of Oncology, 30(1): 19-33, 2019.
  • K. Muro, E. Van Cutsem, Y. Narita, G. Pentheroudakis, E. Baba, J. Li, M.-H. Ryu, W. I. Wan Zamaniah, W.-P. Yong, K.-H. Yeh, K. Kato, Z. Lu, B. C. Cho, I. M. Nor, M. Ng, L.-T. Chen, T. E. Nakajima, K. Shitara, H. Kawakami, T. Tsushima, T. Yoshino, F. Lordick, E. Martinelli, E. C. Smyth, D. Arnold, H. Minami, J. Tabernero & J.-Y. Douillard.
11. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
  • BMC Cancer,97(2):94-101, 2019.
  • Tadamichi Denda, Daisuke Sakai, Tetsuya Hamaguchi, Naotoshi Sugimoto, Takashi Ura, Kentaro Yamazaki, Hirofumi Fujii, Takeshi Kajiwara, Takako Eguchi Nakajima, Shin Takahashi, Satoshi Otsu, Yoshito Komatsu, Fumio Nagashima, Toshikazu Moriwaki, Taito Esaki, Takeo Sato, Michio Itabashi, Eiji Oki, Toru Sasaki, Yoshinori Sunaga, Samira Ziti-Ljajic, Claire Brillac, Takayuki Yoshino.
12. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.
  • Cancer Science, 110(3): 1032-1043, 2019.
  • Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, Yamaguchi T, Tatematsu N, Okayama T, Morikawa A, Mouri T, Tanaka H, Kimura M, Imai H, Mizukami T, Imoto A, Kondoh C, Shiotsu S, Okuyama H, Ueno M, Takahashi T, Tsuji T, Aragane H, Inui A, Higashiguchi T, Takayama K.
《2017年度》

《原著・総説》

1. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients.
  • Asia-Pacific Journal of Clinical Oncology. 13(2): e132-137, 2017.4.
  • Tetsuji Terazawa, Hitoshi Nishitani, Ken Ksato, Hironobu Hashimoto, Kohei Akiyoshi, Yuriko Ito, Akihiro Nakamoto, Satoru Iwasa, Takako Eguchi Nakajima, Tetsuya Hamaguchi, Yasuhide Yamada and Yasuhiro Shimada.
2. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.
  • Int J Oncol. 50(6): 2049-2058, 2017.6.
  • Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K.
3. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
  • Int J Cancer. 141(6): 1222-1230, 2017.9.
  • Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ.
4. Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy.
  • OncoTargets and Therapy. 10, 4599-4605, 2017.9.
  • Sunakawa Y, Izawa N, Mizukami T, Horie Y, Hirakawa M, Arai H, Ogura T, Tsuda T, Nakajima TE.
5. Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorecatal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size.
  • ESMO open. 2(5), 2017.10.
  • Sakamaki K, Kito Y, Yamazaki K, Izawa N, Tsuda T, Morita S, Boku N.
6. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
  • Ann Oncol. 28(11): 2780-2785, 2017.11.
  • Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ.
7. Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.
  • Oncotarget. 8(66): 110530-110539, 2017.11.
  • Arai H, Miyakawa K, Denda T, Mizukami T, Horie Y, Izawa N, Hirakawa M, Ogura T, Tsuda T, Sunakawa Y, and Nakajima TE.
8. CEA response and depth of response (DpR) to predict clinical outcomes of first-line cetuximab treatment for metastatic colorectal cancer.
  • Targeted Oncology. 12(6): 787-794, 2017.12.
  • Yu Sunakawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Masahiro Takeuchi, Masashi Fujii, and Wataru Ichikawa.
9. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
  • Annals of Oncology. 29: 44-70, 2018.01.
  • T. Yoshino, D. Arnold, H. Taniguchi, G. Pentheroudakis, K. Yamazaki, R.-H. Xu, T. W. Kim, F. Ismail, I. B. Tan, K.-H. Yeh, A. Grothey, S. Zhang, J. B. Ahn, M. Y. Mastura, D. Chong, L.-T. Chen, S. Kopetz, T. Eguchi-Nakajima, H. Ebi, A. Ohtsu, A. Cervantes, K. Muro, J. Tabernero, H. Minami, F. Ciardiello & J.-Y. Douillard.
10. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version).
  • J Anus Rectum Colon. 2(Suppl. I) : 1-51, 2018.01.
  • Hideyuki Ishida, Tatsuro Yamaguchi, Kohji Tanakaya, Kiwamu Akagi, Yasuhiro Inoue, Kensuke Kumamoto, Hideki Shimodaira, Shigeki Sekine, Toshiaki Tanaka, Akiko Chino, Naohiro Tomita, Takeshi Nakajima, Hirotoshi Hasegawa, Takao Hinoi, Akira Hirasawa, Yasuyuki Miyakura, Yoshie Murakami, Kei Muro, Yoichi Ajioka, Yojiiro Hashiguchi, Yoshinori Ito, Yutaka Saito, Testuya Hamaguchi, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Hiroshi Kawano, Yusuke Kinugasa, Norihiro Kokudo, Keiko Murofushi, Takako Nakajima, Shiro Oka, Yoshiharu Sakai, Akihiko Tsuji, Keisuke Uehara, Hideki Ueno, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Narikazu Boku, Takahiro Fujimori, Michio Itabashi, Nobuo Koinuma, Takayuki Morita, Genichi Nishimura, Yuh Sakata, Yasuhiro Shimada, Keiichi Takahashi, Shinji Tanaka, Osamu Tsuruta, Toshiharu Yamaguchi, Kenichi Sugihara, Toshiaki Watanabe and Japanese Society for Cancer of the Colon and Rectum.
11. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
  • Clin Cancer Res. 24(4): 784-793, 2018.02.
  • Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ.
12. Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.
  • J Clin Oncol. 36(10): 1000-1006, 2018.02.
  • Yuka Ito, Takashi Tsuda, Hiroko Minatogawa, Sayaka Kano, Kentaro Sakamaki, Masahiko Ando, Koichiro Tsugawa, Yasuyuki Kojima, Naoki Furuya, Kunihiro Matsuzaki, Mamoru Fukuda, Sadatoshi Sugae, Ichiro Ohta, Hitoshi Arioka, Yutaka Tokuda, Kazutaka Narui, Ayako Tsuboya, Takashi Suda, Satoshi Morita, Narikazu Boku, Takeharu Yamanaka, and Takako Eguchi Nakajima.
13. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.
  • Int J Clin Oncol. 23(1): 1-34, 2018.2.
  • Toshiaki Watanabe, Kei Muro, Yoichi Ajioka, Yojiro Hashiguchi, Yoshinori Ito, Yutaka Saito, Tetsuya Hamaguchi, Hideyuki Ishida, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Hiroshi Kawano, Yusuke Kinugasa, Norihiro Kokud, Keiko Murofushi, Takako Nakajima, Shiro Oka, Yoshiharu Sakai, Akihito Tsuji, Keisuke Uehara, Hideki Ueno, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Narikazu Boku, Takahiro Fujimori, Michio Itabashi, Nobuo Koinuma, Takayuki Morita, Genichi Nishimura, Yuh Sakata, Yasuhiro Shimada, Keiichi Takahashi, Shinji Tanaka, Osamu Tsuruta, Toshiharu Yamaguchi, Naohiko Yamaguchi, Toshiaki Tanaka, Kenjiro Kotake, Kenichi Sugihara, Japanese Society for Cancer of the Colon and Rectum.
14. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan.
  • J ESMO open,2018.3.
  • Taro Funakoshi, Takahiro Horimatsu, Michio Nakamura, Koichi Shiroshita, Koichi Suyama, Masashi Mukoyama, Takuro Mizukami, Tsutomu Sakurada, Eishi Baba, Kazuhiko Tsuruya, Akira Nozaki, Kensei Yahata, Yukinori Ozaki, Yoshifumi Ubara, Hisateru Yasui, Akihiro Yoshimoto, Shingo Fukuma, Naoya Kondo, Takeshi Matsubara, Kazuo Matsubara, Shunichi Fukuhara, Motoko Yanagita, Manabu Muto.
《2016年度》

《原著・総説》

1. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective coparison.
  • Mol Clin Oncol. 4(4): 603-606, 2016.2.
  • Tsuda T, Kyomori C, Mizukami T, Taniyama T, Izawa N, Horie Y, Hirakawa M, Ogura T, Nakajima T, Tsugawa K, Boku N
2. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. Mol Carcinog. 2016.2.
  • Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K
3. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17:99-108, 2016.
  • DOI: http://dx.doi.org/10.1016/S1470-2045(15)00410-6
  • Shuichi Hironaka, Naotoshi Sugimoto, Kensei Yamaguchi,Toshikazu Moriwaki, Yoshito Komatsu, Tomohiro Nishina, Akihito Tsuji, Takako Eguchi Nakajima, Masahiro Gotoh, Nozomu Machida, Hideaki Bando, Taito Esaki, Yasunori Emi, Takashi Sekikawa, Shigemi Matsumoto, Masahiro Takeuchi, Narikazu Boku, Hideo Baba, Ichinosuke Hyodo.
4. Phase I/II study of nab‐paclitaxel plus gemcitabine for chemotherapy‐naive Japanese patients with metastatic pancreatic cancer.
  • Cancer Chemother Pharmacol DOI 10.1007/s00280-016-2972-3
  • Hideki Ueno, Masafumi Ikeda, Makoto Ueno, Nobumasa Mizuno, Tatsuya Ioka, Yasushi Omuro, Takako Eguchi Nakajima, Junji Furuse.
5. Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205).
  • Gastric cancer epub DOI 10.1007/S10120-016-0610-8
  • Shitara K, Doi T, Nagano O, Imamura CK, Ozeki T, Ishii Y, Tsuchihashi K, Takahashi S, Nakajima TE, Hironaka S, Fukutani M, Hasegawa H, Saya H, Ohtsu A.
6. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
  • Annals of Oncology epub DOI:10.1093/annonc/mdw206
  • Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T,Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I.
《2015年度》

《原著・総説》

1. Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
  • Int J Clin Oncol. 20(3): 455-462, 2015.9.
  • Izawa N, Onozawa Y, Hikosaka T, Hamauchi S, Tsushima T, Todaka A, Machida N, Haraguchi Y, Ogawa H, Nishimura T, Nakagawa M, Fuke T, Iida Y, Kamijo T, Onitsuka T, Boku N, Yasui H, Yokota T
2. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
  • Int J Oncol. 47(2): 499-505, 2015.7.
  • Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakajima TE, Boku N, Nishio K
3. Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure
  • Mol Clin Oncol. 3(5): 1029-1034, 2015.1
  • Yoshiki Horie, Kentaro Yamazaki, Taro Funakoshi, Satoshi Hamauchi, Hiroya Taniguchi, Takahiro Tsushima, Akiko Todaka, Nozomu Machida, Keisei Taku, Akira Fukutomi, Yusuke Onozawa, Hirofumi Yasui, Takuro Mizukami, Naoki Izawa, Mami Hirakawa, Takashi Tsuda, Takako Nakajima, Narikazu Boku
4. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients.
  • Asia-Pacific Journal of Clinical Oncology 2015 Aug 6 [Epub ahead of print]. doi: 10.1111/ajco.12405.
  • Terazawa T, Nishitani H, Kato K, Hashimoto H, Akiyoshi K, Ito Y, Nakamoto A, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Shimada Y.
《2014年度》

《原著・総説》

1. HER2-positive gastric cancer
  • Gastric Cancer. 17(1): 1-12, 2014.1.
  • Boku N
2. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
  • Invest New Drugs. 32(2): 261-270, 2014.4.
  • Boku N, Muro K, Machida N, Hashigaki S, Kimura N, Suzuki M, Lechuga M, Miyata Y
3. Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients.
  • Jpn J Clin Oncol. 44(3): 214-223, 2014.1.
  • Boku N, Sugihara K, Kitagawa Y, Hatake K, Gemma A, Yamazaki N, Muro K, Hamaguchi T, Yoshino T, Yana I, Ueno H, Ohtsu A
4. How can we improve adjuvant chemotherapy for colon cancer?
  • Lancet Oncology. 15(3): 1413-1415, 2014.11.
  • Boku N
5. Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients.
  • Gastric Cancer 2014; 17: 54-60. doi: 10.1007/s10120-013-0238-x
  • Kawano A, Nakajima TE, Oda I, Hokamura N, Iwasa S, Kato K, Hamaguchi T, Yamada Y, Fujii H, Shimada Y.
6. The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
  • Anticancer Research 2014; 34: 1053-1056.
  • Terazawa T, Nishitani H, Kato K, Hashimoto H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Shimada Y.
7. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX Study).
  • The oncologist 2014; 19: 1-2. doi: 10.1634/theoncologist.2014-0159
  • Hamamoto Y, Yamaguchi T, Nishina T, Yamazaki K, Ura T, Nakajima T, Goto A, Shimada K, Nakayama N, Sakamoto J, Morita S, Yamada Y.

PAGE TOP